Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 and Nivolumab in HBV-related HCC
NCT04233840Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Feb 2019
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04233840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233840.